Lymphoma Therapy
Allo-PBSCT with RIC feasible for children with refractory Hodgkin disease
Published in Cancer Weekly, May 4th, 2004
"Despite high-dose chemotherapy and autografting, the outcome for patients with primary refractory Hodgkin's disease (HD) or multiple relapses remains unsatisfactory," hematologists in Germany explained.
In a study conducted by A. Claviez and colleagues at the University of Kiel, "[s]ix pediatric patients (median age: 16 years, range: 11-19) received reduced intensity conditioning and allogeneic peripheral blood stem-cell transplantation (PBSCT) after failure of stratified first-line chemotherapy, involved-field radiotherapy, and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2004-05-04)
More Articles from Cancer Weekly
- Breast & GI Cancer
Sentinel node biopsy should be standardized - Cancer
Updated nausea and vomiting treatment guidelines offered to cancer patients - Cancer Outcomes
There may be a link between Internet use and cancer outcomes - Diagnostics
Researchers develop polarized reflectance spectroscopy for precancer detection - Oncogenesis
Oncogenesis from single base mutation in IRES of Epstein-Barr nuclear antigen 1 - Acute Lymphoblastic Leukemia
Molecular analyses of ALL suggest strategies for more effective treatments - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
